Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Prevymis, letermovir, Date of authorisation: 08/01/2018, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Ovaleap, follitropin alfa, Date of authorisation: 27/09/2013, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): HyQvia, human normal immunoglobulin, Date of authorisation: 16/05/2013, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Inflectra, infliximab, Date of authorisation: 10/09/2013, Revision: 32, Status: Authorised

Start of procedure - extension of marketing authorisation (26 April - 22 May 2025)

Start of procedure: Type II variation - extension of indication (26 April - 22 May 2025)

Human medicines European public assessment report (EPAR): Ixchiq, Chikungunya vaccine (live), Date of authorisation: 28/06/2024, Revision: 2, Status: Authorised

Minutes of the CHMP meeting 9-12 December 2024

Overview of (invented) names reviewed in April 2025 by the Name Review Group (NRG) adopted at the CHMP meeting of 22 May 2025